Alexandre Le Vert

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes

J. Marvel, Y. Leverrier, G. Boivin, 2019, npj Vaccines.

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine

G. Leroux-Roels, P. Moris, I. Leroux-Roels, 2022, Frontiers in Immunology.

Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results

P. van Damme, I. De Coster, N. Cools, 2021, The Journal of infectious diseases.

OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza

J. Marvel, Y. Leverrier, Fergal Hill, 2021, Frontiers in Immunology.

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

P. Moss, H. McShane, A. Lawrie, 2016, Vaccine.

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

F. Salguero, T. Courant, F. Boué, 2023, Frontiers in Immunology.

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.

G. Leroux-Roels, Yorick Janssens, I. Leroux-Roels, 2023, The Lancet. Infectious diseases.